載入...

Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting

The use of targeted therapeutics known as poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the management of ovarian cancer is currently transforming clinical practice. The PARP inhibitor rucaparib is indicated in the UK, European Union and the United States for use in the treatmen...

全面介紹

Na minha lista:
書目詳細資料
發表在:Ther Adv Med Oncol
Main Authors: Tookman, Laura, Krell, Jonathan, Nkolobe, Baleseng, Burley, Laura, McNeish, Iain A.
格式: Artigo
語言:Inglês
出版: SAGE Publications 2020
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7257860/
https://ncbi.nlm.nih.gov/pubmed/32523631
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920921980
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!